EP 0980258 A1 20000223 - SUPPRESSION OF TUMOR NECROSIS FACTOR ALPHA AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN THERAPY
Title (en)
SUPPRESSION OF TUMOR NECROSIS FACTOR ALPHA AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN THERAPY
Title (de)
UNTERDRÜCKUNG DES ALPHA-TUMORNEKROSEFAKTORS UND DES WACHSTUMSFAKTORS DER VASKULAREN ENDOTHELZELLEN IN THERAPEUTISCHEN BEHANDLUNGEN
Title (fr)
SUPPRESSION THERAPEUTIQUE DU FACTEUR DE NECROSE TUMORALE ALPHA ET DU FACTEUR DE CROISSANCE DES CELLULES ENDOTHELIALES VASCULAIRES
Publication
Application
Priority
- GB 9801343 W 19980512
- US 85488197 A 19970512
Abstract (en)
[origin: WO9851344A1] Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed are compositions comprising a TNF alpha antagonist and a VEGF antagonist. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.
IPC 1-7
IPC 8 full level
A61K 31/00 (2006.01); A61K 31/454 (2006.01); A61K 31/505 (2006.01); A61K 38/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 29/00 (2006.01); A61P 37/00 (2006.01); A61P 37/02 (2006.01); A61P 43/00 (2006.01); C07K 16/24 (2006.01)
CPC (source: EP)
A61K 31/00 (2013.01); A61K 31/505 (2013.01); A61K 39/3955 (2013.01); A61P 29/00 (2017.12); A61P 37/00 (2017.12); A61P 37/02 (2017.12); A61P 43/00 (2017.12); C07K 16/241 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01)
Citation (search report)
See references of WO 9851344A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9851344 A1 19981119; AU 7345798 A 19981208; CA 2290021 A1 19981119; EP 0980258 A1 20000223; EP 1170017 A1 20020109; HK 1044887 A1 20021108; JP 2001525816 A 20011211
DOCDB simple family (application)
GB 9801343 W 19980512; AU 7345798 A 19980512; CA 2290021 A 19980512; EP 01117491 A 19980512; EP 98920669 A 19980512; HK 02105101 A 20020709; JP 54891198 A 19980512